Naji Duraid Hamid, Tan Chengcheng, Han Fabin, Zhao Yuanyuan, Wang Junhan, Wang Dan, Fa Jingjing, Li Sisi, Chen Shanshan, Chen Qiuyun, Xu Chengqi, Wang Qing K
Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology and Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
The Institute for Translational Medicine, The Second Affiliated Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
Mol Genet Genomics. 2018 Feb;293(1):119-128. doi: 10.1007/s00438-017-1365-6. Epub 2017 Sep 11.
The tissue factor pathway inhibitor (TFPI) gene encodes a protease inhibitor with a critical role in regulation of blood coagulation. Some genomic variants in TFPI were previously associated with plasma TFPI levels, however, it remains to be further determined whether TFPI variants are associated with other coagulation factors. In this study, we carried out a large population-based study with 2313 study subjects for blood coagulation data, including fibrinogen levels, prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT). We identified significant association of TFPI variant rs10931292 (a functional promoter variant with reduced transactivation) with increased plasma fibrinogen levels (P = 0.017 under a recessive model), but not with PT, APTT or TT (P > 0.05). Using a large case-control association study population with 4479 CAD patients and 3628 controls, we identified significant association between rs10931292 and CAD under a recessive model (OR 1.23, P = 0.005). For the first time, we show that a TFPI variant is significantly associated with fibrinogen levels and risk of CAD. Our finding contributes significantly to the elucidation of the genetic basis and biological pathways responsible for fibrinogen levels and development of CAD.
组织因子途径抑制剂(TFPI)基因编码一种蛋白酶抑制剂,在血液凝固调节中起关键作用。TFPI中的一些基因组变异先前与血浆TFPI水平相关,然而,TFPI变异是否与其他凝血因子相关仍有待进一步确定。在本研究中,我们对2313名研究对象进行了一项基于人群的大型研究,以获取血液凝固数据,包括纤维蛋白原水平、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)和凝血酶时间(TT)。我们发现TFPI变异rs10931292(一种具有降低反式激活作用的功能性启动子变异)与血浆纤维蛋白原水平升高显著相关(隐性模型下P = 0.017),但与PT、APTT或TT无关(P > 0.05)。使用一个包含4479例CAD患者和3628例对照的大型病例对照关联研究人群,我们在隐性模型下发现rs10931292与CAD之间存在显著关联(OR 1.23,P = 0.005)。我们首次表明,一种TFPI变异与纤维蛋白原水平和CAD风险显著相关。我们的发现对阐明负责纤维蛋白原水平和CAD发生的遗传基础及生物学途径有重大贡献。